EZH2 inhibitor

DRUG CLASS:

EZH2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
SMARCB1 negative	Chordoma	SMARCB1 negative	Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
SMARCB1 negative	Spindle Cell Sarcoma	SMARCB1 negative	Spindle Cell Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 deletion	Soft Tissue Sarcoma	SMARCB1 deletion	Soft Tissue Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 mutation	Sarcoma	SMARCB1 mutation	Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	PARP inhibitor + EZH2 inhibitor Sensitive: C3 – Early Trials PARP inhibitor + EZH2 inhibitor Sensitive : C3	PARP inhibitor + EZH2 inhibitor Sensitive: C3 – Early Trials PARP inhibitor + EZH2 inhibitor Sensitive : C3
SMARCB1 A240fsX28	Sarcoma	SMARCB1 A240fsX28	Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 deletion	Soft Tissue Sarcoma	SMARCB1 deletion	Soft Tissue Sarcoma	SHR-2554 Sensitive: C3 – Early Trials SHR-2554 Sensitive : C3	SHR-2554 Sensitive: C3 – Early Trials SHR-2554 Sensitive : C3
TP63 rearrangement	Lymphoma	TP63 rearrangement	Lymphoma	valemetostat Sensitive: C4 – Case Studies valemetostat Sensitive : C4	valemetostat Sensitive: C4 – Case Studies valemetostat Sensitive : C4
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D
EZH2 overexpression	Adrenal Cortex Carcinoma	EZH2 overexpression	Adrenal Cortex Carcinoma	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D	EZH2 inhibitor Sensitive: D – Preclinical EZH2 inhibitor Sensitive : D
EZH2 Y646	Melanoma	EZH2 Y646	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D	CPI-169 + CPI-203 Sensitive: D – Preclinical CPI-169 + CPI-203 Sensitive : D
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D	CPI-169 Sensitive: D – Preclinical CPI-169 Sensitive : D
EZH2 Y641	Lymphoma	EZH2 Y641	Lymphoma	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D	HM97594 Sensitive: D – Preclinical HM97594 Sensitive : D
BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	BCL2 fusion + EZH2 mutation	Diffuse Large B Cell Lymphoma	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D	venetoclax + tazemetostat Sensitive: D – Preclinical venetoclax + tazemetostat Sensitive : D
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 Y646F	Non-Hodgkin’s Lymphoma	EZH2 Y646F	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 A682G	Non-Hodgkin’s Lymphoma	EZH2 A682G	Non-Hodgkin’s Lymphoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D	JQEZ5 Sensitive: D – Preclinical JQEZ5 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D	UNC1999 Sensitive: D – Preclinical UNC1999 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D	dabrafenib + JQEZ5 Sensitive: D – Preclinical dabrafenib + JQEZ5 Sensitive : D

EZH2 inhibitor

EZH2 inhibitor

Associations(48)

Associations
(48)